Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Trial Profile

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 08 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Sep 2018 Planned End Date changed from 1 Aug 2024 to 1 Nov 2024.
    • 10 Sep 2018 Planned primary completion date changed from 1 Aug 2023 to 1 Nov 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top